齐拉西酮与利培酮治疗精神分裂症的疗效比较

Comparison of the efficacy between Ziprasidone and Risperidone treatment for Schizophrenia

目的探讨齐拉西酮与利培酮治疗精神分裂症的临床疗效、副反应及对生活质量的影响。方法将98例符合诊断标准的精神分裂症患者随机分为两组,每组49例,分别给予齐拉西酮(齐拉西酮组)和利培酮(利培酮组)治疗,并用阳性和阴性症状量表(PANSS)评定临床疗效,用实验室的相关检查和不良反应量表(TESS)评定不良反应,用精神分裂症患者生活质量量表(SQLS)评定患者的生活质量。结果治疗8周后,两组患者的PANSS量表总减分率相比较差异无统计学意义(P>0.05);两组患者的不良反应总发生率相比较差异也无统计学意义(P>0.05);但齐拉西酮组患者的生活质量改善明显优于利培酮组,且差异有显著性(P<0.01)。结论齐拉西酮与利培酮治疗精神分裂症具有相当的疗效,且副反应发生率也相当,但齐拉西酮在改善患者生活质量方面却明显优于利培酮。

Objective To discuss the clinical efficacy and side effects of the Ziprasidone and Risperidone treatment for the Schizophrenia, and its impact on patients＇ quality of life. Methods 98 patients with Schizophrenia were randomly divided into two groups, 49 cases in each group, and were treated by the Ziprasidone （ziprasidone groups） and Risperidone （risperidone group） , and to evaluate the clinical efficacy with the positive and negative syndrome scale （PANSS）, used the treatment emergent symptom scale（TESS） and laboratory tests to assess the untoward reaction, and used the Schizophrenia quality of life scale （SQLS） to assess patient＇s quality of Life. Results After 8 weeks, the total reduction rate of the PANSS in two groups had no different statistically significance （P 〈 0.05） ; the adverse reactions overall incidence of phase also had no different statistical significance （P 〈 0.05） ; but the patient＇s quality of life of the Ziprasidone group was significantly better than the Risperidone group, and had different sta- tistically significant （P 〈 0.01）. Conclusions Ziprasidone and Risperidone in the treatment of Schizophrenia has considerable efficacy, and adverse reactions are few, but Ziprasidone in improving the quality of life of patients is significantly superior to Risperidone.